Ablative SolutionsÂ’ technology involves endovascular catheters to provide an efficacious, durable, cost-effective and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.
United States of America
- (03.Sep.2019) Ablative Solutions Announces Positive 12-Month Results From Study Evaluating Company's Novel Therapy for Uncontrolled Hypertension
- (23.Jul.2019) Ablative Solutions Announces Enrollment and Randomization of First Patient in Global Clinical Trial Evaluating Company's Novel Therapy for Uncontrolled Hypertension
- (11.Jul.2019) Ablative Solutions Announces Appointment of Kate Rumrill as President and Chief Executive Officer
- (07.Mar.2019) Ablative Solutions Announces Results From Treatment of Patients With Hypertension in the European Peregrine Post-Market Study
- (03.Jan.2019) Ablative Solutions, Inc. Announces $77 Million Financing for Unique Therapeutic Approach to Treating Uncontrolled Hypertension